Low anonymous voting compliance with the novel policy for managing conflicts of interest implemented in the 9th version of the american college of chest physicians antithrombotic guidelines

Simple item page
dc.contributor.advisor
dc.contributor.authorNeumann, Ignacio
dc.contributor.authorAkl, Elie
dc.contributor.authorValdes, Macarena
dc.contributor.authorBravo, Stephanie
dc.contributor.authorAraos, Silvana
dc.contributor.authorKairouz, Kairouz
dc.contributor.authorSchünemann, Holger
dc.contributor.authorGuyatt, Gordon
dc.date.accessioned2017-04-13T12:20:30Z
dc.date.available2017-04-13T12:20:30Z
dc.date.issued2013
dc.description.abstractBACKGROUND: The executive committee of the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (AT9) developed a strategy to limit the impact of conflict of interest (COI) on recommendations. This policy excluded conflicted panelists from voting on recommendations with which they had conflicts. The objective of the study is to explore the compliance of the attendees of the AT9 final conference. METHODS: We conducted a survey and reviewed public declarations of COI of all the final AT9 conference attendees. For each of the controversies on which voting occurred (nine of 628 total recommendations), we estimated the compliance with COI policy as the proportion of attendees who recused themselves from voting on controversies for which they were conflicted. To evaluate the potential effect of noncompliance, we assumed that every vote cast by an ineligible conference attendee was cast in direction of the majority vote. RESULTS: Sixty-three panelists voted in at least one controversy at the final conference; the percentage of conflicted panelists varied from 6% to 39% for eight controversies. The compliance with the COI policy was 14 of 14 (100%) for one controversy, and varied from one of 19 (5%) to one of three (33%) in the remaining seven. In two of the eight controversies ("Compression device plus aspirin vs low-molecular-weight heparin in tromboprophylaxis in orthopedic surgery" and "Low-molecular-weight heparin vs vitamin K antagonists for treatment"), the low compliance may have affected the final recommendations. CONCLUSIONS: The low compliance raises concerns about implementation of COI restrictions in the context of anonymous voting.
dc.format.extent6
dc.identifier.citationChest. 2013 Oct;144(4):1111-1116
dc.identifier.urihttp://hdl.handle.net/11447/1139
dc.identifier.urihttp://dx.doi.org/10.1378/chest.13-0169
dc.language.isoen_US
dc.publisherElsevier
dc.subjectConflict of Interest
dc.subjectFibrinolytic Agents/therapeutic use
dc.subjectGuideline Adherence
dc.subjectPractice Guidelines as Topic
dc.subjectSocieties, Medical
dc.subjectThoracic Diseases
dc.titleLow anonymous voting compliance with the novel policy for managing conflicts of interest implemented in the 9th version of the american college of chest physicians antithrombotic guidelines
dc.typeArtículo

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Low Anonymous Voting Compliance With the Novel Policy for Managing Conflicts of Interest Implemented in the 9th Version of the American College of Chest Physicians Antithrombotic Guidelines.pdf
Size:
131.3 KB
Format:
Adobe Portable Document Format
Description:
Texto completo restringido
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services